<sup>18</sup>F‐fluoromisonidazole (FMISO) Positron Emission Tomography (PET) Predicts Early Infarct Growth in Patients with Acute Ischemic Stroke

Lee, Gha-hyun; Kim, Jae Seung; Oh, Seung Jun; Kang, Dong‐Wha; Kim, Jong Seung; Kwon, Sun U.

doi:10.1111/jon.12180

Cited by 8 publications

(6 citation statements)

References 11 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Supporting the findings of 15 O-PET, FMISO uptake has also been seen up to 131 hours after the stroke 85 . These findings suggest potentially salvageable tissue beyond current clinical intervention windows.…”

Section: Fluoromisonidazolesupporting

confidence: 74%

“…FMISO uptake in the acute stage may also be able to predict outcomes, with 80% of those with uptake showing an increase in infarct volume compared to no infarct growth in those without FMISO uptake 85 . This is unsurprising given the nature of the tissue represented by FMISO uptake, but given the limited ability of MRI to differentiate between penumbra and benign oligaemia, this method for quantifying vulnerable tissue may have important implications for prognostication.…”

Section: Fluoromisonidazolementioning

confidence: 99%

See 1 more Smart Citation

PET imaging of the neurovascular interface in cerebrovascular disease

et al. 2017

View full text Add to dashboard Cite

Cerebrovascular disease encompasses a range of pathologies that affect different components of the cerebral vasculature and brain parenchyma. Large artery atherosclerosis, acute cerebral ischaemia, and intracerebral small vessel disease all demonstrate altered metabolic processes that are key to their pathogenesis. Although structural imaging techniques such as MRI are the mainstay of clinical care and research in cerebrovascular disease, they have limited ability to detect these pathophysiological processes in vivo. By contrast, PET can detect and quantify metabolic processes that are relevant to each facet of cerebrovascular disease. Information obtained from PET studies has helped to shape the understanding of key concepts in cerebrovascular medicine, including vulnerable atherosclerotic plaque, salvageable ischaemic penumbra, neuroinflammation and selective neuronal loss after ischaemic insult. PET has also helped to elucidate the relationships between chronic hypoxia, neuroinflammation, and amyloid-β deposition in cerebral small vessel disease. This Review describes how PET-based imaging of metabolic processes at the neurovascular interface has contributed to our understanding of cerebrovascular disease.

show abstract

Section: Fluoromisonidazolesupporting

confidence: 74%

Section: Fluoromisonidazolementioning

confidence: 99%

PET imaging of the neurovascular interface in cerebrovascular disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Three to 5 d is a short but not inconceivable time period in which to obtain and analyze a PET scan. Clinical PET protocols have been developed for imaging patients within 24 h of presentation (53)(54)(55)(56)(57). Most liver transplants in America are performed at fewer than 100 sites (58), suggesting that if a rapid protocol were developed, it would need only to be instituted at a limited number of specialized centers.…”

Section: Implications For Human Studiesmentioning

confidence: 99%

Noninvasive Imaging of Drug-Induced Liver Injury with ¹⁸F-DFA PET

et al. 2018

View full text Add to dashboard Cite

Drug-induced liver failure is a significant indication for a liver transplant, and unexpected liver toxicity is a major reason that otherwise effective therapies are removed from the market. Various methods exist for monitoring liver injury but are often inadequate to predict liver failure. New diagnostic tools are needed. We evaluate in a preclinical model whetherF-2-deoxy-2-fluoroarabinose (F-DFA), a PET radiotracer that measures the ribose salvage pathway, can be used to monitor acetaminophen-induced liver injury and failure. Mice treated with vehicle, 100, 300, or 500 mg/kg acetaminophen for 7 or 21 h were imaged with F-FDG andF-DFA PET. Hepatic radiotracer accumulation was correlated to survival and percentage of nonnecrotic tissue in the liver. Mice treated with acetaminophen and vehicle or -acetylcysteine were imaged withF-DFA PET. F-DFA accumulation was evaluated in human hepatocytes engrafted into the mouse liver. We show that hepatic F-DFA accumulation is 49%-52% lower in mice treated with high-dose acetaminophen than in mice treated with low-dose acetaminophen or vehicle. Under these same conditions, hepaticF-FDG accumulation was unaffected. At 21 h after acetaminophen treatment, hepatic F-DFA accumulation can distinguish mice that will succumb to the liver injury from those that will survive it (6.2 vs. 9.7 signal to background, respectively). HepaticF-DFA accumulation in this model provides a tomographic representation of hepatocyte density in the liver, with a between hepaticF-DFA accumulation and percentage of nonnecrotic tissue of 0.70. PET imaging with F-DFA can be used to distinguish effective from ineffective resolution of acetaminophen-induced liver injury with-acetylcysteine (15.6 vs. 6.2 signal to background, respectively). Human hepatocytes, in culture or engrafted into a mouse liver, have levels of ribose salvage activity similar to those of mouse hepatocytes. Our findings suggest that PET imaging withF-DFA can be used to visualize and quantify drug-induced acute liver injury and may provide information on the progression from liver injury to hepatic failure.

show abstract

“…Besides, 18 F-FMISO uptake was also used to predict the tissue fate. The patients without 18 F-FMISO uptake had no infarct growth on the follow-up DWI, while those with abnormally increased 18 F-FMISO uptake showed grown infarct (100). And white matter was reported to take up more 18 F-FMISO than gray matter, indicating stronger resistance to ischemia than gray matter (101).…”

Section: Pet Metabolic Imagingmentioning

confidence: 97%

Imaging Acute Stroke: From One-Size-Fit-All to Biomarkers

Mei

Hou

et al. 2021

Front. Neurol.

View full text Add to dashboard Cite

In acute stroke management, time window has been rigidly used as a guide for decades and the reperfusion treatment is only available in the first few limited hours. Recently, imaging-based selection of patients has successfully expanded the treatment window out to 16 and even 24 h in the DEFUSE 3 and DAWN trials, respectively. Recent guidelines recommend the use of imaging techniques to guide therapeutic decision-making and expanded eligibility in acute ischemic stroke. A tissue window is proposed to replace the time window and serve as the surrogate marker for potentially salvageable tissue. This article reviews the evolution of time window, addresses the advantage of a tissue window in precision medicine for ischemic stroke, and discusses both the established and emerging techniques of neuroimaging and their roles in defining a tissue window. We also emphasize the metabolic imaging and molecular imaging of brain pathophysiology, and highlight its potential in patient selection and treatment response prediction in ischemic stroke.

show abstract

¹⁸F‐fluoromisonidazole (FMISO) Positron Emission Tomography (PET) Predicts Early Infarct Growth in Patients with Acute Ischemic Stroke

Abstract: FMISO PET scan can predict early infarct growth in acute ischemic stroke patients with perfusion-diffusion mismatch in MRI.

Cited by 8 publications

References 11 publications

PET imaging of the neurovascular interface in cerebrovascular disease

PET imaging of the neurovascular interface in cerebrovascular disease

Noninvasive Imaging of Drug-Induced Liver Injury with ¹⁸F-DFA PET

Imaging Acute Stroke: From One-Size-Fit-All to Biomarkers

Contact Info

Product

Resources

About

18F‐fluoromisonidazole (FMISO) Positron Emission Tomography (PET) Predicts Early Infarct Growth in Patients with Acute Ischemic Stroke

Abstract: FMISO PET scan can predict early infarct growth in acute ischemic stroke patients with perfusion-diffusion mismatch in MRI.

Cited by 8 publications

References 11 publications

PET imaging of the neurovascular interface in cerebrovascular disease

PET imaging of the neurovascular interface in cerebrovascular disease

Noninvasive Imaging of Drug-Induced Liver Injury with 18F-DFA PET

Imaging Acute Stroke: From One-Size-Fit-All to Biomarkers

Contact Info

Product

Resources

About

¹⁸F‐fluoromisonidazole (FMISO) Positron Emission Tomography (PET) Predicts Early Infarct Growth in Patients with Acute Ischemic Stroke

Noninvasive Imaging of Drug-Induced Liver Injury with ¹⁸F-DFA PET